MegaRibavirin aerosol for the treatment of influenza A virus infections in mice

Antiviral Research

Volumn 78, Issue 3, 2008, Pages 223-229

  Gilbert, Brian E ^a   McLeay, Matthew T ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MTM Research LLC   (United States)

Author keywords

Aerosol; Influenza; Mice; Ribavirin; Treatment

Indexed keywords

RIBAVIRIN;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; FEMALE; INFLUENZA; INFLUENZA VIRUS A; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURVIVAL;

AEROSOLS; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MICE; NEBULIZERS AND VAPORIZERS; ORTHOMYXOVIRIDAE INFECTIONS; RIBAVIRIN; TREATMENT OUTCOME;

AVES; CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; MUS;

EID: 41149168072     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.01.005     Document Type: Article

References (38)

1. Boeckh M., Englund J., Li Y., Miller C., Cross A., Fernandez H., Kuypers J., Kim H., Gnann J., Whitley R., and NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin. Infect. Dis. 44 (2007) 245-249
2. Chevaliez S., Brillet R., Lazaro E., Hezode C., and Pawlotsky J.-M. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81 (2007) 7732-7741
3. Chung D.H., Sun Y., Parker W., Arterburn J., Bartolucci A., and Jonsson C.B. Ribavirin reveals a lethal threshold of allowable mutation frequency for hantaan virus. J. Virol. 81 (2007) 11722-11729
4. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6895-6900
5. Crotty S., Maag D., Arnold J.J., Zhong W.D., Lau J.Y.N., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6 (2000) 1375-1379
6. Englund J.A., Piedra P.A., Ahn Y.-M., Gilbert B.E., and Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 125 (1994) 635-641
7. Englund J.A., Piedra P.A., Jefferson L.S., Wilson S.Z., Taber L.H., and Gilbert B.E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 117 (1990) 313-320
8. Galabov A.S., Simeonova L., and Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 17 (2006) 251-258
9. Gilbert B.E., and Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30 (1986) 201-205
10. Gilbert B.E., and Knight V. Ribavirin aerosol as the treatment for influenza. Drugs Today 26 (1990) 195-205
11. Gilbert B.E., Wilson S.Z., Knight V., Couch R.B., Quarles J.M., Dure L., Hayes N., and Willis G. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Chemother. 27 (1985) 309-313
12. Gilbert B.E., and Wyde P.R. Pharmacokinetics of ribavirin aerosol in mice. Antimicrob. Agents Chemother. 32 (1988) 117-121
13. Gilbert B.E., Wyde P.R., Ambrose M.W., Wilson S.Z., and Knight V. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. 17 (1992) 33-42
14. Gilbert B.E., Wyde P.R., Wilson S.Z., and Robins R.K. Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: Pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus. Antimicrob. Agents Chemother. 35 (1991) 1448-1453
15. Iacono A.T., Johnson B.A., Grgurich W.F., Youssef J.G., Corcoran T.E., Seiler D.A., Dauber J.H., Smaldone G.C., Zeevi A., Yousem S.A., Fung J.J., Burckart G.J., McCurry K.R., and Griffith B.P. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. 354 (2006) 141-150
16. Ilyushina N.A., Hoffmann E., Solomon R., Webster R.G., and Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12 (2007) 363-370
17. Ilyushina N.A., Webster R.G., and Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antiviral Res. 74 (2007) A31-A32
18. Knight V., and Gilbert B. Antiviral therapy with small particle aerosols. Eur. J. Clin. Microbiol. Infect. Dis. 7 (1988) 721-731
19. Knight V., and Gilbert B.E. Ribavirin aerosol treatment of influenza. In: Knight V., and Gilbert B.E. (Eds). Infectious Disease Clinics of North America: Antiviral Chemotherapy vol. 1 (1987), W.B. Saunders Co., Philadelphia 441-457
20. Knight V., Koshkina N.V., Waldrep J.C., Giovanella B.C., and Gilbert B.E. Anti-cancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. 44 (1999) 177-186
21. Knight V., McClung H.W., Wilson S.Z., Waters B.K., Quarles J.M., Cameron R.W., Greggs S.E., Zerwas J.M., and Couch R.B. Ribavirin small-particle aerosol treatment of influenza. Lancet 2 8253 (1981) 945-949
22. Knight V., Yu C.P., Gilbert B.E., and Divine G.W. Estimating the dosage of ribavirin aerosol according to age and other variables. J. Infect. Dis. 158 (1988) 443-448
23. Koshkina N.V., Golunski E., Roberts L.E., Gilbert B.E., and Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J. Aerosol Med. 17 (2004) 7-14
24. Krilov L.R. Safety issues related to the administration of ribavirin. Pediatr. Infect. Dis. J. 21 (2002) 479-481
25. McClung H.W., Knight V., Gilbert B.E., Wilson S.Z., Quarles J.M., and Divine G.W. Ribavirin aerosol treatment of influenza B virus infection. J. Am. Med. Assoc. 249 (1983) 2671-2674
26. Phalen R.F. Inhalation Studies: Foundations and Techniques (1984), CRC Press, Inc., Boca Raton
27. Schlesinger R.B. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J. Toxicol. Environ. Health 15 (1985) 197-214
28. Smee D.F., Wong M.-H., Bailey K.W., and Sidwell R.W. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir. Chem. Chemother. 17 (2006) 185-192
29. Subbaraco K., and Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 7 (2007) 267-278
30. Taber L.H., Knight V., Gilbert B.E., McClung H.W., Wilson S.Z., Norton H.J., Thurston J.M., Gordon W.H., Atmar R.L., and Schlaudt W.R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72 (1983) 613-618
31. Verschraegen C.F., Gilbert B.E., Loyer E., Huaringa A., Walsh G., Newman R.A., and Knight V. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 10 (2004) 2319-2326
32. Whimbey E., Champlin R.E., Englund J.A., Mirza N.Q., Piedra P.A., Goodrich J.M., Przepiorka D., Luna M.A., Morice R.C., Neumann J.L., Elting L.S., and Bodey G.P. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 16 (1995) 393-399
33. Wiggins N.A. The development of a mathematical approximation technique to determine the mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of drug particles in an inhalation aerosol spray. Drug Dev. Ind. Pharm. 17 (1991) 1971-1986
34. Wilson S.Z., Gilbert B.E., Quarles J.M., Knight V., McClung H.W., Moore R.V., and Couch R.B. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob. Agents Chemother. 26 (1984) 200-203
35. Wyde P.R., Couch R.B., Mackler B.F., Cate T.R., and Levy B.M. Effects of low- and high-passage influenza virus infection in normal and nude mice. Infect. Immun. 15 (1977) 221-229
36. Wyde P.R., Wilson S.Z., Gilbert B.E., and Smith R.H.A. Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol. Antimicrob. Agents Chemother. 30 (1986) 942-944
37. Wyde P.R., Wilson S.Z., Petrella R., and Gilbert B.E. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 7 (1987) 211-220
38. Yen H.L., Ilyushina N.A., Salomon R., Hoffmann E., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor resistant recombinant A/Vietnan/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81 (2007) 12418-12426